Skip to main content

Table 1 Patient characteristics in all patients

From: Prognostic and functional impact of perioperative LAMA/LABA inhaled therapy in patients with lung cancer and chronic obstructive pulmonary disease

  Patients with COPD (n = 130)
LAMA/LABA LAMA p value* No-BD P value**
n = 64 n = 23 n = 43
Age 73.4 ± 6.7 70.6 ± 6.5 0.045 70.5 ± 6.2 0.027
Sex      
 Male 50 (78.1) 19 (82.6) 0.644 39 (90.7) 0.088
 Female 14 (21.9) 4 (17.4)   4 (9.3)  
Smoking status      
 Current smoker 25 (39.0) 11 (47.8) 0.466 18 (41.9) 0.772
 Ex-smoker 39 (61.0) 12 (52.2)   25 (58.1)  
Tobacco, pack-years 53.2 ± 27.3 60.6 ± 29.4 0.301 63.8 ± 40.2 0.052
Pulmonary function      
 FEV1 (mL) 1787.5 ± 558.8 1429.5 ± 412.5 0.005 2168.8 ± 535.2  < 0.001
 FEV1/FVC (%) 58.3 ± 9.6 53. 4 ± 11.4 0.049 61.4 ± 10.2 0.106
 FEV1%pred (%) 85.3 ± 22.6 64.3 ± 12.4  < 0.001 94.6 ± 2.9 0.017
Severity of AFL      
 Mild 32 (50.0) 1 (4.4)  < 0.001 36 (83.7)  < 0.001
 Moderate to severe 32 (50.0) 22 (95.6)   7 (16.3)  
Comorbidities      
 Cardiovascular disease 38 (59.4) 13 (56.5) 0.812 33 (76.7) 0.575
 Diabetes mellitus 17 (26.6) 6 (26.1) 0.964 12 (27.9) 0.878
Surgical procedure      
 Pneumonectomy 1 (1.6) 0 0.367 0 0.844
 Lobectomy 56 (87.5) 23 (100.0)   40 (93.0)  
 Segmentectomy 2 (3.1) 0   1 (2.3)  
 Partial resection 5 (7.8) 0   2 (4.7)  
Histology      
 Adenocarcinoma 31 (48.4) 6 (26.1) 0.172 26 (60.5) 0.450
 Squamous cell carcinoma 28 (43.8) 14 (60.9)   15 (34.9)  
 Other 5 (7.8) 3 (13.0)   2 (4.7)  
Pathologic staging      
 I 50 (78.1) 11 (47.8) 0.014 33 (76.7) 0.411
 II 8 (12.5) 9 (39.1)   3 (7.0)  
 III 6 (9.4) 3 (13.0)   7 (16.3)  
Recurrence (present) 7 (10.9) 11 (47.8)  < 0.001 15 (34.9) 0.003
  1. Data are presented as n (%) or as mean ± SD
  2. COPD Chronic obstructive pulmonary disease; LAMA long-acting muscarinic antagonists; LABA long-acting β2-agonists; BD bronchodilator; FEV1 forced expiratory volume in 1 s; FEV1%pred percentage of predicted forced expiratory volume in 1 s; FVC forced vital capacity; AFL airflow limitation
  3. *Significance of LAMA/LABA versus LAMA
  4. **Significance of LAMA/LABA versus No-BD